Lung Therapeutics completes $14.3M Series B financing to develop treatments for lung disease

Lung Therapeutics, a pharmaceutical company establishing new treatments for niche drug indications in fibrosis, lung injuries and diseases, announced Tuesday that it raised $14.3 million in a Series B financing.

 

The capital will support ongoing clinical trials in multiple locations and advance development for Lung Therapeutics' "transformative" drug for fibrosis, LTI-03.

The company has now raised $17 million in outside funding, aside from the $27 million awarded for discovery research and development.

The latest raise was headed by Bios Partners, a life sciences private equity firm out of Dallas and Fort Worth, Texas.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars